ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
0,00%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,515
-0,21%
Bitcoin
65 300,07
0,51%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) Actualités

IBRX ImmunityBio Inc

6,2694
0,4394 (7,54%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ImmunityBio Inc IBRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,4394 7,54% 6,2694 01:59:04
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,84 5,80 6,35 6,23 5,83
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202400:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202422:36EDGAR2Form 8-K - Current report
07/6/202415:13BWImmunityBio Announces 2024 Annual Meeting of Stockholders..
17/5/202415:00BWConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep..
09/5/202423:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202414:00BWImmunityBio Completes GMP Drug Substance Manufacturing..
02/5/202422:04BWImmunityBio, Serum Institute of India Agree on an Exclusive..
30/4/202414:00BWImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to..
25/4/202406:03BWImmunityBio Announces Positive Overall Survival Results of..
23/4/202403:56BWImmunityBio Announces FDA Approval of ANKTIVA®,..
06/3/202415:00BWNIAID-Sponsored Study Shows N-803 Combined with Neutralizing..
05/3/202415:00BWN-803 Combined with Natural Killer Cells Showed Potential to..
26/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/2/202403:28EDGAR2Form 8-K - Current report
21/2/202415:00BWImmunityBio Announces Full Accrual of First Two Phases of..
07/2/202403:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:00BWImmunityBio Quality-of-Life Study in BCG-Unresponsive..
03/2/202401:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202401:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202403:59EDGAR2Form SC 13D/A - General statement of acquisition of..
04/1/202403:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202403:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202412:08EDGAR2Form 8-K - Current report
02/1/202412:00BWImmunityBio Announces $320 Million Investment by Oberland..
16/11/202315:00BWImmunityBio to Participate in 35th Annual Piper Sandler..
09/11/202303:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202315:00BWFirst Data for ImmunityBio’s Memory Cytokine-Enriched NK..
26/10/202318:03DJNImmunityBio Shares Rally as FDA Accepts N-803 Resubmission
26/10/202315:00BWFDA Accepts ImmunityBio’s BLA Resubmission as Complete and..
23/10/202317:00DJNImmunityBio Shares 11% Higher on License Application..
23/10/202315:00BWImmunityBio Announces Biological License Application..
28/9/202312:06EDGAR2Form DEF 14C - Other definitive information statements
22/9/202321:06EDGAR2Form D - Notice of Exempt Offering of Securities
21/9/202322:25EDGAR2Form SC 13D/A - General statement of acquisition of..
11/9/202312:25EDGAR2Form 8-K - Current report
11/9/202312:00BWImmunityBio Announces $470 Million Equity and Debt Financing..
07/9/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202301:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202314:30EDGAR2Form 8-K - Current report
29/8/202311:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
29/8/202303:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202302:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202311:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..

Dernières Valeurs Consultées

NASDAQ
IBRX
ImmunityBio
BIT
P1ZYN1
NLBNPIT1ZYN1 20991231 27...
NASDAQ
HMIN
Homeinns Hotel Group
TG
A190V2
United States of America
USOTC
BTEAF
Beneteau (PK)
UNSW3
HPOETH
Hippopotamus
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés